UK-based liquid biopsy firm Angle said today that it has inked a comarketing agreement with Qiagen for circulating tumor cell (CTC) technology.
UK-based liquid biopsy firm Angle said today that it has inked a comarketing agreement with Qiagen for circulating tumor cell (CTC) technology.